Executive Vice President, Oncology R&D, AstraZeneca
Appears in 1 story
Defending the camizestrant filing before ODAC
For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
